This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 74.1 kDa. The protein migrates as 130-150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris, Glycine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD27 Ligand, Fc Tag (active trimer) (MALS verified) on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human CD27 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5266) is more than 85% in HP-SEC, and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.
Immobilized Human CD27, His Tag (Cat. No. CD7-H522b) at 2 μg/mL (100 μL/well) can bind Human CD27 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5266) with a linear range of 0.2-8 ng/mL (QC tested).
Serial dilutions of Anti-CD27 Ligand (cusatuzumab) Antibody, Human IgG1 were added into Human CD27 Ligand, Fc Tag (active trimer) (MALS verified) (Cat. No. CDL-H5266): Biotinylated Human CD27, Fc,Avitag (Cat. No. TN7-H82F6) binding reactions. The half maximal inhibitory concentration (IC50) is 0.74034 μg/mL (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $2310.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.